Theravance Biopharma (TBPH) SVP has shares withheld for RSU taxes

Rhea-AI Filing Summary

Theravance Biopharma SVP Aine Miller reported a routine tax-withholding transaction related to equity compensation. On the vesting of previously granted restricted stock units, 6,827 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations in a transaction with the issuer, not the open market. After this withholding, Miller directly holds 177,334 Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Miller Aine

Role SVP, DEV & HEAD OF IRE OFFICE

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares	6,827	$16.55	$113K

Holdings After Transaction: Ordinary Shares — 177,334 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 6,827 shares Withholding price: $16.55 per share Shares held after transaction: 177,334 shares

3 metrics

Shares withheld for taxes 6,827 shares Tax-withholding disposition on RSU vesting

Withholding price $16.55 per share Value used for tax-withholding shares

Shares held after transaction 177,334 shares Direct ownership following tax withholding

Key Terms

restricted stock units, tax obligations, open market transaction, Ordinary Shares

4 terms

restricted stock units financial

"arising out of the vesting of previously granted restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligations financial

"Shares withheld to satisfy tax obligations arising out of the vesting"

open market transaction financial

"did not involve an open market transaction"

An open market transaction is a buy or sell of publicly traded securities executed on an exchange or other public trading venue where many buyers and sellers can participate. It matters to investors because these trades change the visible supply and demand for a stock—like shoppers moving prices in a busy marketplace—affecting share price, liquidity (how easily you can trade), and sometimes the balance of ownership.

Ordinary Shares financial

"security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Aine

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, DEV & HEAD OF IRE OFFICE

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/20/2026		F		6,827(1)	D	$16.55	177,334	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Theravance Biopharma (TBPH) executive Aine Miller report on this Form 4?

Aine Miller reported a tax-withholding disposition tied to vesting restricted stock units. 6,827 Ordinary Shares were withheld at $16.55 per share to cover tax obligations, in a transaction with Theravance Biopharma rather than an open market sale.

How many Theravance Biopharma shares were withheld for taxes on Aine Miller’s RSU vesting?

The filing shows 6,827 Ordinary Shares withheld to satisfy tax obligations from vesting restricted stock units. The shares were valued at $16.55 each, and this withholding was executed with the issuer, not through open market trading or a discretionary sale.

Did Aine Miller sell Theravance Biopharma (TBPH) shares on the open market in this Form 4?

No, the Form 4 specifies the transaction did not involve an open market transaction. Shares were withheld by the issuer solely to satisfy tax obligations from vesting restricted stock units, which is a common, mechanistic equity compensation event.

How many Theravance Biopharma shares does Aine Miller hold after this tax-withholding event?

Following the tax-withholding transaction, Aine Miller directly holds 177,334 Ordinary Shares of Theravance Biopharma. This figure reflects her remaining ownership after 6,827 shares were withheld to cover taxes arising from the vesting of restricted stock units.

What is the transaction code F in Aine Miller’s Theravance Biopharma Form 4?

Transaction code F indicates payment of a tax liability or exercise price by delivering securities. Here, 6,827 shares of Theravance Biopharma were withheld at $16.55 per share to satisfy tax obligations from vesting restricted stock units, rather than being sold in the market.